|Title||Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity.|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Jensen, Brian C., and Howard L. McLeod|
|Date Published||2013 Jan|
|Keywords||Antineoplastic Agents, Cardiotoxins, Genetic Association Studies, Heart Failure, Humans, Pharmacogenetics, Risk|
Damage to the heart can result from both traditional chemotherapeutic agents, such as doxorubicin, and newer 'targeted' therapies, such as trastuzumab. This chemotherapeutic cardiotoxicity is potentially life-threatening and necessitates limiting or discontinuing an otherwise-effective cancer treatment. Clinical strategies focus on surveillance rather than prevention, although there are no specific therapies for this highly morbid adverse effect. Current models for prospectively predicting risk of chemotherapeutic cardiotoxicity are limited. Cardiotoxicity can occur idiosyncratically in patients without obvious demographic risk factors, suggesting a genetically determined susceptibility, and candidate-gene studies have identified a limited number of variants that increase risk. In this commentary we indicate a need for more powerful means to identify risk prospectively, and suggest that broad pharmacogenomic approaches may be fruitful.
|Original Publication||Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity.|
|PubMed Central ID||PMC3582022|
|Grant List||K08 HL096836 / HL / NHLBI NIH HHS / United States |
UL1 RR025747 / RR / NCRR NIH HHS / United States
P01CA142538 / CA / NCI NIH HHS / United States
P01 CA142538 / CA / NCI NIH HHS / United States
K08HL96836 / HL / NHLBI NIH HHS / United States
Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity.